JP2018500376A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500376A5
JP2018500376A5 JP2017535007A JP2017535007A JP2018500376A5 JP 2018500376 A5 JP2018500376 A5 JP 2018500376A5 JP 2017535007 A JP2017535007 A JP 2017535007A JP 2017535007 A JP2017535007 A JP 2017535007A JP 2018500376 A5 JP2018500376 A5 JP 2018500376A5
Authority
JP
Japan
Prior art keywords
methyl
pyrazolo
alkyl
aryl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017535007A
Other languages
English (en)
Japanese (ja)
Other versions
JP6649388B2 (ja
JP2018500376A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067831 external-priority patent/WO2016109515A1/en
Publication of JP2018500376A publication Critical patent/JP2018500376A/ja
Publication of JP2018500376A5 publication Critical patent/JP2018500376A5/ja
Application granted granted Critical
Publication of JP6649388B2 publication Critical patent/JP6649388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017535007A 2014-12-30 2015-12-29 ユビキチン特異的プロテアーゼ7阻害薬としてのピロロ及びピラゾロピリミジン Active JP6649388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098141P 2014-12-30 2014-12-30
US62/098,141 2014-12-30
PCT/US2015/067831 WO2016109515A1 (en) 2014-12-30 2015-12-29 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Publications (3)

Publication Number Publication Date
JP2018500376A JP2018500376A (ja) 2018-01-11
JP2018500376A5 true JP2018500376A5 (enExample) 2019-01-31
JP6649388B2 JP6649388B2 (ja) 2020-02-19

Family

ID=55310894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535007A Active JP6649388B2 (ja) 2014-12-30 2015-12-29 ユビキチン特異的プロテアーゼ7阻害薬としてのピロロ及びピラゾロピリミジン

Country Status (22)

Country Link
US (4) US9902728B2 (enExample)
EP (2) EP3240791B1 (enExample)
JP (1) JP6649388B2 (enExample)
KR (1) KR102581827B1 (enExample)
CN (1) CN107406451B (enExample)
AR (1) AR103297A1 (enExample)
AU (2) AU2015374170B2 (enExample)
CA (1) CA2972797C (enExample)
CL (1) CL2017001687A1 (enExample)
CO (1) CO2017006997A2 (enExample)
EA (1) EA038204B1 (enExample)
EC (1) ECSP17049010A (enExample)
ES (1) ES2768996T3 (enExample)
IL (1) IL252773A0 (enExample)
MA (1) MA40706A1 (enExample)
MX (2) MX373788B (enExample)
PH (1) PH12017501224A1 (enExample)
SA (1) SA517381839B1 (enExample)
SG (1) SG11201704897QA (enExample)
TW (2) TWI770525B (enExample)
WO (1) WO2016109515A1 (enExample)
ZA (1) ZA201704746B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
AU2016222556B2 (en) 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
WO2017144633A1 (en) * 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
WO2017201683A1 (en) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
FR3061177B1 (fr) * 2016-12-28 2019-09-27 Les Laboratoires Servier Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109563094B (zh) 2016-06-10 2022-03-18 法国施维雅药厂 新的(杂)芳基取代的哌啶基衍生物、它们的制备方法和含有它们的药物组合物
WO2018009812A1 (en) 2016-07-08 2018-01-11 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
SG11201903483VA (en) 2016-10-28 2019-05-30 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
CN108239082B (zh) * 2016-12-26 2021-01-05 成都先导药物开发股份有限公司 一种抑制rock的化合物及其应用
JP7365238B2 (ja) 2017-03-21 2023-10-19 テンプル・ユニバーシティ-オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 5-ヒドロキシトリプタミン受容体7調節物質および治療剤としてのその使用
WO2018175188A1 (en) * 2017-03-21 2018-09-27 Temple University-Of The Commonwealth System Of Higher Education Novel modulators of the sigma-2 receptor and their method of use
MX2020002944A (es) 2017-09-14 2020-09-28 Daiichi Sankyo Co Ltd Compuesto que tiene estructura ciclica.
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
AR113846A1 (es) * 2017-11-29 2020-06-17 Servier Lab Derivados de piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
EP3724191B9 (en) 2017-12-15 2022-05-18 Pyramid Biosciences, Inc. 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
US11919902B2 (en) 2017-12-22 2024-03-05 Hibercell, Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
US11779018B2 (en) 2018-03-30 2023-10-10 Sumitomo Chemical Company, Limited Heterocyclic compound and arthropod pest control composition containing same
DK3784661T3 (da) 2018-04-25 2024-02-12 Bayer Ag Hidtil ukendte heteroaryl-triazol- og heteroaryl-tetrazol-forbindelser som pesticider
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
CA3113547A1 (en) 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition
KR20210100127A (ko) * 2018-12-06 2021-08-13 알막 디스커버리 리미티드 치료용 usp19 억제제
MX2021006540A (es) * 2018-12-06 2021-07-07 Almac Discovery Ltd Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19).
KR102712818B1 (ko) 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CN109666005A (zh) * 2018-12-14 2019-04-23 上海毕得医药科技有限公司 一种2-溴恶唑-5-甲酸乙酯的合成方法
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
EP3923987A1 (en) 2019-02-14 2021-12-22 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
WO2020207352A1 (zh) * 2019-04-11 2020-10-15 四川科伦博泰生物医药股份有限公司 三嗪酮并咪唑类化合物及其医药用途
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
AU2021255613A1 (en) * 2020-04-15 2022-09-29 Pyramid Biosciences, Inc. Methods for preparing tyrosine receptor kinase inhibitors
EP4144722A4 (en) 2020-04-27 2024-05-22 Autotac Inc. Compound as ubr box domain ligand
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
TW202227405A (zh) * 2020-08-24 2022-07-16 以色列商安道麥馬克西姆有限公司 用於製備經取代的吡唑之方法
WO2022159650A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2
EP4304586A4 (en) 2021-03-10 2025-04-02 Jnana Therapeutics Inc. SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023004291A1 (en) * 2021-07-19 2023-01-26 Baylor College Of Medicine Coronavirus main protease inhibitors and methods using same
AU2022315201A1 (en) * 2021-07-20 2024-01-18 Dana-Farber Cancer Institute, Inc. Inhibitors targeting ubiquitin specific protease 7 (usp7)
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
JP2024534014A (ja) 2021-08-20 2024-09-18 バイオメア フュージョン,インコーポレイテッド 癌の処置のための不可逆的メニン-MLL阻害剤、N-[4-[4-(4-モルホリニル)-7H-ピロロ[2,3-d]ピリミジン-6-イル]フェニル]-4-[[3(R)-[(1-オキソ-2-プロペン-1-イル)アミノ]-1-ピペリジニル]メチル]-2-ピリジンカルボキサミドの結晶形態
GB202200753D0 (en) * 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN121219276A (zh) 2023-05-25 2025-12-26 巴斯夫欧洲公司 内酰胺杀有害生物化合物
EP4467535A1 (en) 2023-05-25 2024-11-27 Basf Se Lactam pesticidal compounds
WO2025038421A1 (en) * 2023-08-11 2025-02-20 Jnana Therapeutics Inc. Bicyclic heteroaryl-containing piperidine inhibitors of slc6a19 function
CN118496138B (zh) * 2024-07-10 2024-12-03 西北农林科技大学深圳研究院 一种l-氮杂环丁烷-2-羧酸的合成方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
IN151496B (enExample) 1980-02-26 1983-05-07 Chamanlal Jagannath Shishoo
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US20120165319A1 (en) 1995-12-20 2012-06-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
DK0982992T3 (da) 1997-05-08 2002-10-14 Aventis Cropscience Uk Ltd Anvendelse af thienopyrimidiner som fungicider
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
US20030153598A1 (en) 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
ES2222389T3 (es) 2000-06-07 2005-02-01 Almirall Prodesfarma, S.A. Derivados de 6-fenilpirrolopirimidindiona.
WO2002000655A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
PE20020394A1 (es) * 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US20020169175A1 (en) 2001-02-05 2002-11-14 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of heterocyclic compounds
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
WO2003092606A2 (en) 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004037176A2 (en) * 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
ES2289377T3 (es) 2003-03-18 2008-02-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Nuevas pirazolopirimidonas y su uso como inhibidores de pde.
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
CA2536887C (en) 2003-08-26 2012-03-06 Teijin Pharma Limited Pyrrolopyrimidinone derivatives
WO2005035003A2 (en) 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
JP4809228B2 (ja) 2003-09-24 2011-11-09 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
WO2005095360A1 (en) 2004-04-02 2005-10-13 Prana Biotechnology Limited Neurologically-active compounds
WO2006004201A1 (ja) 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. 神経再生促進剤
US20060135507A1 (en) 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
US20060172992A1 (en) 2004-08-13 2006-08-03 Eisai Co., Ltd. Therapeutic agent for overactive bladder resulting from cerebral infarction
US20090118261A1 (en) 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
US20080064680A1 (en) 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
EP1829877A4 (en) 2004-12-24 2009-10-14 Dainippon Sumitomo Pharma Co BICYCLIC PYRROLE DERIVATIVES
EP1876179B1 (en) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
RU2008129873A (ru) 2005-12-23 2010-01-27 Новартис АГ (CH) Конденсированные гетероциклические соединения, полезные в качестве ингибиторов дпп-iv
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
CN101686952A (zh) 2007-03-12 2010-03-31 Vm生物医药公司 新型钙离子通道调节剂
CN101730703B (zh) 2007-03-16 2012-12-26 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
US20100184706A1 (en) * 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
RU2341527C1 (ru) 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
RU2345996C1 (ru) 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
US8648085B2 (en) * 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2274308A1 (en) 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110082158A1 (en) 2008-10-01 2011-04-07 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US8927718B2 (en) 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
BR112012008518A2 (pt) 2009-10-13 2016-04-05 Msd Oss Bv derivado heterocíclico, e, composição farmacêutica
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
US8575114B2 (en) 2010-03-23 2013-11-05 Albany Molecular Research, Inc. SGLT-2 inhibitors, methods of making them, and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
JP2014515345A (ja) * 2011-01-10 2014-06-30 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸シンターゼ阻害剤としてのピリミジノン誘導体
GB201107768D0 (en) 2011-05-10 2011-06-22 Univ Manchester Riboswitches
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201348226A (zh) 2012-02-28 2013-12-01 Amgen Inc 作為pim抑制劑之醯胺
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 mGluR1 길항제로 작용하는 사이에노피리미디논 유도체
CN103833646A (zh) 2014-02-28 2014-06-04 广东工业大学 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Similar Documents

Publication Publication Date Title
JP2018500376A5 (enExample)
US8962596B2 (en) 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
KR101659193B1 (ko) Btk 활성의 억제제로서의 헤테로아릴 피리돈 및 아자-피리돈 화합물
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP6123804B2 (ja) 3環性ヘテロ環化合物及びjak阻害剤
US8871761B2 (en) NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
JP6401709B2 (ja) Atrキナーゼ阻害剤として有用な化合物
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
JP6054967B2 (ja) 置換アネレート化ピリミジンおよびその使用
JP2015522002A5 (enExample)
JP2016525092A5 (enExample)
AU2019257450A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
KR20200101400A (ko) 아릴 및 헤테로아릴 치환된 인돌 화합물
MX2012010050A (es) Inhibidores de pirrolopirazina cinasa.
FI3436461T3 (fi) Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
AU2011224484A1 (en) Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
TW200800213A (en) Novel imidazo based heterocycles
JP2016525072A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP2018530557A (ja) 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用
WO2014064131A2 (en) Inhibitors of bruton's tyrosine kinase
JP2023527827A (ja) Il-17aモジュレーター
US20250206752A1 (en) Pi3k inhibitors
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
KR20210083287A (ko) 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
JP7611900B2 (ja) 縮合複素環化合物